We had previously reported that tetramethyl-O-NGDA (M4N), a synthetic
derivative of the naturally occurring nordihydroguaiaretic acid (NDGA)
, is able to inhibit HIV Tat transactivation by blocking host Sp1 prot
ein at the Sp1 cognate binding site on the HIV LTR promoter. The prese
nt studies were undertaken to examine whether M4N is able to inhibit t
he replication of herpes simplex virus (HSV), another Sp1-regulated vi
rus. The results showed that in Vero cells, M4N inhibits at micromolar
levels (IC50 = 43.5 mu M) the expression of the herpes immediate earl
y gene (alpha-ICP4), which is essential for HSV replication. An electr
ophoretic mobility shift assay, examining Spl binding to the alpha-ICP
4 promoter, showed a significant inhibition of the control bands: 88%
inhibition of the fast moving band (FMB) and 45% of the slow moving ba
nd (SMB), at 100 mu M of drug concentration. Comparative studies betwe
en M4N and acycloguanosine (acyclovir, ACV) in cultured Vero cells rev
ealed an interesting pattern in the drug sensitivity (IC50) and cytoto
xicity (TC50) parameters. For M4N, the IC50 varied between 11.7 and 4
mu M in 10 passages of HSV-1 and 4 passages of HSV-2 with no indicatio
n for a requirement of higher drug concentration. In contrast, for acy
clovir, the IC50 increased from 7 mu M in the first passage to 444 mu
M in the tenth passage of HSV-1, and > 88 mu M for the fourth passage
of HSV-2, indicating a rapid build-up of drug resistance against acycl
ovir. While the selective index (SI), defined as the ratio: TC50/IC50,
remained relatively constant for M4N; it dropped 60-fold for acyclovi
r in the endpoints of viral passages; Drug sensitivity for M4N toward
the acyclovir-sensitive strain (sm44) and the acyclovir-resistant stra
in (ACV-10) of HSV-1 was similar, indicating no cross-resistance betwe
en M4N and acyclovir in their anti-HSV effects. These results may have
an important clinical relevance since HSV has been shown to be a fact
or for spreading of HIV.